# INFLAMMATORY BOWEL DISEASE

## 定義

• **Ulcerative colitis (UC):** inflammation of the colonic _mucosa; contiguous_, starting at rectum

• **Crohn’s disease (CD):** _transmural_ inflammation anywhere along GI tract, _skip lesions_

## Epidem & pathophys (_Lancet_ 2016;387:156 & 2017;390:2769)

• Prevalence ~1-3:1000 in N Am; ↑ incidence in Caucasians, Jews, newly industrialized

• Age of onset 15–30 y; ? bimodal with 2nd peak at 50–70 y; 1:1 M:F in N America

• Smokers at ↑ risk for CD, whereas nonsmokers & former smokers at ↑ risk for UC

• Genetic predisposition + environmental risk factors → T cell dysregulation → inflammation

# ULCERATIVE COLITIS (_Lancet_ 2018;389:1756)

## 臨床表現

• **Grossly bloody diarrhea**, lower abdominal cramps, urgency, tenesmus

• Extracolonic (>25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers, uveitis, episcleritis, thromboembolic events (esp. during a flare; _Lancet_ 2010;375:657), AIHA, seroneg arthritis, chronic hepatitis, cirrhosis, PSC (↑ risk cholangio CA, CRC)

• Multiple scores for assessing dis. severity clinically: Truelove & Witts; SCCAI

## Diagnosis

• **Colonoscopy:** involves rectum (95%) & extends prox., usu circumfer., & _contig. within colon_

• Location: proctitis (30–60%), L-sided (15–45%) and extensive (pancolitis; 15–35%)

• Appearance: vascularity loss, friable mucosa, diffuse ulceration, _pseudopolyps_ (chronicity)

• Histology: superficial chronic inflammation; crypt abscesses & architectural distortion

• Barium enema with featureless and tubular appearance of colon (_leadpipe appearance_)

• Flares: ↑ ESR & CRP (not Se or Sp); ⊕ fecal calprotectin helpful in distinguishing IBD vs. IBS and monitoring for IBD flare (_Gastro Hep_ 2017;13:53)

## Complications

• **Toxic megacolon** (5%): colon dilatation (≥6 cm on KUB), colonic atony, systemic toxicity, & ↑ risk of perf. Rx with IV steroids & broad-spectrum 抗生素; surgery if needed.

• Stricture (rectosigmoid), dysmotility, anorectal dysfxn after recurrent inflammation

• CRC and dysplasia (_see below_)

• For 病人 s/p surgery with ileal pouch, may develop _pouchitis_ (inflammation of ileal pouch, up to ½ of 病人). Rx with 抗生素 (MNZ, cipro), probiotics.

## Prognosis

• 50% in remission at any given time. Intermittent exacerbations in 90%; continual active disease in ~18%. Prox progression in 25% at 10 y. Rate of colectomy at 10 y is 24%.

• Mortality rate of severe UC flare is <2%, & overall life expectancy in UC = non-UC 病人

# CROHN’S DISEASE (_Lancet_ 2018;389:1741)

## 臨床表現 (_Nat Rev Gastro Hep_ 2016;13:567)

• **Abdominal pain**, loose/frequent stools (up to 50% ⊕ FOBT), fever, malaise, wt loss

• Mucus-containing, **nongrossly bloody diarrhea**

• N/V, bloating, obstipation if presence of obstruction; extracolonic 表現 as in UC

• Multiple scoring systems: CD Activity Index (CDAI), Harvey-Bradshaw Index

## Diagnosis

• **Ileocolonoscopy + bx** along with **small bowel assessment** (eg, MR-enterography)

• Small bowel/ileitis (~25%), ileocolonic (~50%), colonic (~25%); isolated upper tract rare

• Appearance: nonfriable mucosa, cobblestoning, aphthous ulcers, deep & long **fissures**

• Histology: **transmural inflammation** with mononuclear cell infiltrate, **noncaseating granulomas** (seen in <25% of mucosal biopsies), fibrosis, ulcers, fissures

• Montreal classification: age at dx, disease location & behavior (stricturing vs. nonstricturing, penetrating vs. nonpenetrating), plus modifiers for upper tract & perianal disease

## Complications

• **Perianal disease:** fissures, fistulas, skin tags, perirectal abscesses (in 24% of 病人; perianal disease _precedes_ intestinal symptomatology)

• **Stricture:** small bowel, postprandial abd pain; can lead to complete SBO & require surgery

• **Fistulas:** perianal, enteroenteric, rectovaginal, enterovesicular, enterocutaneous

• **Abscess:** fever, tender abd mass, ↑ WBC; _steroids mask sx_, ∴ need high-level suspicion

• **Malabsorption:** ileal disease/resection: ↓ bile acids abs → gallstones; ↓ fatty acid abs → Ca oxalate kidney stones; ↓ fat-soluble vitamin abs → vit D deficiency → _osteopenia_

## Prognosis

• Variable at 1 y: ~50% in remission, ~20% flare, ~20% low activity, ~10% chronic active

• At 20 y, majority will have required some surgery; overall life expectancy is slightly ↓

MANAGEMENT (_Lancet_ 2016;398:1756; _Mayo Clin Proc_ 2017;92:1088)

## Initial evaluation

• **H&P** (✔ for intestinal & extraintestinal 表現) and **dx studies** as above

• **Lab:** consider CBC/diff, LFTs, iron studies, B12, folate, vit D, ESR, CRP, fecal calprotectin

• **Exclude other 原因:** infectious (espec. TB), ischemic colitis, intestinal lymphoma, CRC, IBS, vasculitis, Behçet’s, celiac disease, small intestinal bacterial overgrowth

• **排除 infection** (esp. TB, HBV, CMV) before treating with immunosuppressants and biologics (although not all acutely hospitalized 病人 with IBD need infxn 排除 prior to Rx)

## Goals of 治療 (_Ther Adv Gastro_ 2015;8:143)

• Induce remission of acute flare → maintain remission; mucosal healing 1° goal

• Step up Rx (least → most toxic) typical approach; consider early biologic if severe disease

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Medical Therapy for IBD</b></p></td></tr><tr><td colspan="2"><p><b><i>Ulcerative Colitis</i></b></p></td></tr><tr><td><p><b>Mild</b></p></td><td><p><b>5-ASA:</b> many formulations (sulfasalazine, mesalamine, olsalazine, balsalazide) depending on disease location. Used for induction &amp; maintenance of remission. Complications: diarrhea, abd pain, pancreatitis.</p></td></tr><tr><td><p><b>Mild- moderate</b></p></td><td><p><b>MMX-budesonide:</b> PO budesonide released throughout colon for flare. 1<sup>st</sup>-pass metab ↓ systemic adverse effects of steroid.</p></td></tr><tr><td><p><b>Moderate-severe</b></p></td><td><p><b>PO prednisone:</b> 40–60 mg with taper over several wks to induce remission</p><p><b>AZA/6-MP:</b> 0.5–1 mg/kg and uptitrate over several wks for maintenance; ↑ remission rate when AZA combined with IFX (<span><i>Gastro</i> 2014;146:392)</span>. Complic: BM suppression, lymphoma, pancreatitis, hepatitis; ✔ TPMT levels prior to dosing to ↓ risk of generation of toxic metabs. In selected cases, add allopurinol to boost activity in non-responders.</p></td></tr><tr><td><p><b>Severe or refractory disease</b></p><p>(<span><i>Lancet</i> 2014; 384:309 &amp; 2017;389:1218; <span><i>NEJM</i></span> 2016; 374:1754 &amp; 2017; 76:1723; <span><i>JAMA</i></span> 2019; 321:156)</span></p></td><td><p><b>IV steroids:</b> eg, 100 mg hydrocort q8h or 16–20 mg methylpred q8h to induce remission with plan to taper &amp; switch to non-steroid maintenance.</p><p><b>Cyclosporine:</b> for severe flares refractory to steroids, 2–4 mg/kg infusion × 7 d with goal to Δ to maintenance medication (eg, AZA/6-MP)</p><p><b>Anti-TNF</b> (infliximab, adalimumab &amp; golimumab): for steroid-refractory flares or to maintain remission. Complic: reactiv. TB (✔ PPD prior to Rx) or viral hepatitis; small ↑ risk NHL; lupus-like rxn, psoriasis, MS, CHF.</p><p><i>For TNF refractory, alternative biologic for induction &amp; maintenance:</i> <b>vedolizumab</b> (α4β7 integrin inhibitor); <b>tofacitinib</b> (JAK inh)</p><p><i>Investigational:</i> fecal microbiota transplant (mixed data – efficacy may depend on mode of delivery &amp; prep); etrolizumab (α4β7 inhib); ozanimod (sphinosine-1-phosphate receptor agonist)</p></td></tr><tr><td colspan="2"><p><b><i>Crohn’s Disease</i></b></p></td></tr><tr><td><p><b>Mild</b></p></td><td><p>Consider <b>5-ASA</b> for colonic Crohn’s disease</p><p><b>抗生素:</b> FQ/MNZ or amo x/clav for pyogenic complic (fistulas, perineal dis.)</p></td></tr><tr><td><p><b>Mild-mod</b></p></td><td><p><b>Budesonide:</b> PO, but pH ± time-dep release → ileum &amp; ascending colon</p></td></tr><tr><td><p><b>Moderate-severe</b></p></td><td><p><b>PO prednisone:</b> same as UC, for inducing remission, not maintenance</p><p><b>AZA/6-MP:</b> same as UC; ↑ remission with AZA+IFX (<span><i>NEJM</i> 2010; 362:1383)</span></p><p><b>MTX:</b> 15–25 mg IM/SC or PO qwk for maintenance; 1–2 mo to take effect</p></td></tr><tr><td><p><b>Severe or refractory disease</b> (<span><i>NEJM</i> 2016; 375:1946)</span></p></td><td><p><b>Anti-TNF:</b> infliximab, adalimumab or certolizumab (pegylated)</p><p>If flare on infliximab, ✔ trough &amp; presence of anti-inflixi Ab. Low &amp; ⊖ Ab → ↑ dose/freq. If ⊕ Ab → Δ to other biologic (<span><i>Am J Gastro</i> 2011;106:685)</span>.</p><p><b>Vedolizumab</b> (anti-α4β7 integrin); <b>ustekinumab</b> (anti-IL 12/23)</p><p><i>Investigational:</i> tofacitinib and filgotinib (JAK-inh; <span><i>Lancet</i> 2017;389:266</span>); adipose- derived stem cells <span>(<i>Lancet</i> 2016; 388:1281)</span></p></td></tr></tbody></table>

## Surgery

• **UC:** colectomy if sx refractory to or intolerable side effects from meds, CRC, perforation, toxic megacolon, uncontrolled hemorrhage. Often _ileal pouch-anal anastomosis_ (IPAA).

• **CD:** resection if refractory disease; endoscopic dilation or surgery for strictures; diverting ileostomy for perineal disease

Cancer screening (_NEJM_ 2015;372:1441)

• **Colon cancer:** risk in UC ~2% at 10 y, ~8% at 20 y, ~18% at 30 y. Similar for colonic CD, plus risk of small bowel cancer as well. Dysplasia best marker for risk. Other risk factors include: PSC, ⊕ FHx, greater extent of disease, stricture, & pseudopolyps.

• **Surveillance:** _colonoscopy_ with random bx 8 y after dx to eval for dysplasia, q1–3y thereafter based on risk factors. _Chromoendoscopy_ using dye to stain high-risk lesions for targeted bx is emerging technique. If high-grade dysplasia or dysplasia-assoc. lesion/mass → colectomy.
